SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

___________

FORM 8-K

___________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): ~~July~~December 2814, 2010

PROTECTUS MEDICAL DEVICES, INC.

(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)

Delaware		000-53100		98-0541881
(STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION)		(COMMISSION FILE NO.)		(IRS EMPLOYEE IDENTIFICATION NO.)

110 First Avenue NE, Suite #1006

Minneapolis, MN 55413

(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)

612-379-3975

(ISSUER TELEPHONE NUMBER)

(FORMER NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT)

––––––––––––––––

Copies to:

Gregg E. Jaclin, Esq.

Anslow + Jaclin, LLP

195 Route 9 South, Suite 204

Manalapan, New Jersey 07726

(732) 409-1212

––––––––––––––––

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

1Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers

~~Item~~John 4D.01 ~~Changes~~Olinger inhas ~~Registrant’s~~resigned ~~Certifying~~as ~~Accountant~~our Chairman of the Board of Directors and Chief Intelligence Officer effective December 14, 2010. At the time of resignation, Mr. Olinger was not a member of any committee on the Board of Directors. Mr. Olinger resigned due to personal reasons. His resignation was not the result of any disagreement with us on any matter relating to our operations, policies or practices.

At this time, we intend to continue business operations without a Chief Intelligence Officer. On ~~July~~December 2814, 2010, ~~Bartolomei~~John ~~Pucciarelli,~~S. ~~LLC~~Salstrom ~~(“Bartolomei”)~~was ~~resigned~~appointed as our ~~independent~~Chairman ~~registered~~of ~~public~~the ~~accounting~~Board ~~firm~~of Directors. WeDr. ~~engaged~~Salstrom ~~CCR,~~has ~~LLP~~over ~~(“CCR”)~~thirty toyears ~~serve~~of asexperience ~~our~~with ~~new~~start-up ~~independent~~companies, ~~registered~~mainly ~~public~~in ~~accounting~~biotechnology ~~firm~~and onmedical ~~July~~technology. ~~28, 2010~~Dr. ~~Pursuant~~Salstrom todoes ~~Item~~not ~~304(a)~~have ofany ~~Regulation~~family ~~S-K~~relationship ~~under~~with ~~the~~any ~~Securities~~other ~~Act~~director or executive officer of ~~1933,~~Protectus asMedical ~~amended~~Devices, ~~and~~Inc. ~~under~~As of the ~~Securities~~date ~~Exchange Act~~ of ~~1934~~this filing, asDr. ~~amended,~~Salstrom wehas ~~report~~not asbeen ~~follows:~~appointed to any committee of the Board of Directors.

(a)	(i)	Bartolomei resigned as our independent registered public accounting firm effective on July 28, 2010.
	(ii)	For the two most recent fiscal years ended December 31, 2009 and 2008, Bartolomei’s report on the financial statements did not contain any adverse opinions or disclaimers of opinion, and were not qualified or modified as to uncertainty, audit scope, or accounting principles, other than for a “going concern” uncertainty.
	(iii)	The engagement of CCR was approved by our board of directors.
	(iv)	We and Bartolomei did not have any disagreements with regard to any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure for the audited financials for the fiscal years ended December 31, 2009 and 2008, and subsequent interim period through the date of its resignation, which disagreements, if not resolved to the satisfaction of Bartolomei, would have caused it to make reference to the subject matter of the disagreements in connection with its reports.
	(v)	During our fiscal years ended December 31, 2009 and 2008, and subsequent interim period through the date of dismissal, we did not experience any reportable events, except that in its letter to us on May 31, 2010 regarding our internal control, Bartolomei identified the following material weaknesses and significant deficiencies in our internal control, which constitutes a reportable event set forth in Item 304(a)(1)(v) of Regulation S-K:
		Material Weaknesses:
			1. We do not have written documentation of internal control policies and procedure.
			2. We lack a formal process and timeline for closing the books at the end of each reporting period.
			3. We do not have sufficient segregation of duties within accounting functions, which is a basic internal control.
			4. We do not have review and supervision procedures for financial reporting functions.
		Significant Deficiencies:
			1. We have an inadequate design of controls over recording accruals, proper identification and recording of compensation items and the resultant payroll tax liabilities.
		A material weakness is a deficiency, or a combination of control deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control over financial reporting that is less severe than a material weakness; yet important enough to merit attention by those responsible for oversight of the company’s financial reporting. We intend to take appropriate and reasonable steps to make the necessary improvements to remediate these deficiencies, including:
		●	We will continue to educate our management personnel to comply with the disclosure requirements of Securities Exchange Act of 1934, as amended, and Regulation S-K; and
		●	We will increase management oversight of accounting and reporting functions in the future.
		●	We will document a formal code of ethics.
		●	We will revise processes to provide for a greater role of independent board members in the oversight and review until such time that we are adequately capitalized to permit hiring additional personnel to address segregation of duties issues, ineffective controls over the revenue cycle and insufficient supervision and review by our corporate management.
		●	We will continue to update the documentation of our internal control processes, including formal risk assessment of our financial reporting processes.
		Our board of directors discussed the reportable event with Bartolomei and we authorized Bartolomei to report fully to inquires of its successor accountant concerning the reportable event pursuant to Item 304(a)(1)(v) of Regulation S-K.
(b)	(i)	On July 28, 2010, we engaged CCR to serve as our independent registered public accounting firm.
		Prior to engaging CCR, we had not consulted CCR regarding the application of accounting principles to a specified transaction, completed or proposed, the type of audit opinion that might be rendered on our financial statements or a reportable event, nor did we consult with CCR regarding any disagreements with our prior auditor on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of the prior auditor, would have caused it to make a reference to the subject matter of the disagreements in connection with its reports.
	(ii)	We did not have any disagreements with CCR and therefore did not discuss any past disagreements with CCR.
(c)		We requested Bartolomei to provide a letter addressed to the SEC stating whether it agrees with the statements made by us regarding Bartolomei.

John S. Salstrom, Ph.D., President, CEO, Chairman, Secretary and Director

2Dr. Salstrom is a co-founder of Protectus Medical Devices, Inc. and its wholly-owned subsidiary, SquareOne Medical, Inc. He has over thirty years of experience with start-up companies, mainly in biotechnology and medical technology, and brings a unique ability to analyze and develop strategic plans, business models and optimal corporate structure. Prior to joining SquareOne Medical, Inc., since 1980, Dr. Salstrom served as Head of the Vector Development Program at Molecular Genetics, Inc., Research Director of the Molecular Biology and Human Healthcare Programs at Endotronics, Inc. and he was a Co-Founder and Vice President of Scientific Affairs at Helix BioCore, Inc. He also co-founded and served as Director for Ganesh Energene Ltd. (Mumbai), an Indian Joint Venture. Dr. Salstrom is a Microbiologist and Molecular Biologist by training, having received his B.A. from Miami University, his M.S. and Ph.D. degrees from the University of Wisconsin, followed by a Postdoctoral fellowship at Harvard University. He holds numerous Academic Honors and Awards, several patents, and has to his credit numerous publications, articles, theses and manuscripts. Dr. Salstrom has held several research and teaching positions.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Exhibit No.		Description
16.1		Letter from Bartolomei Pucciarelli LLC, dated August 2, 2010
17.1		Letter of Resignation from John D. Olinger, dated December 14, 2010

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PROTECTUS MEDICAL DEVICES, INC.
Date: August 2, 2010	By: /s/ John S. Salstrom
Date: December 23, 2010	By: /s/ John S. Salstrom
	John S. Salstrom, Ph.D. Chief Executive Officer

Filing Compare · PROTECTUS MEDICAL DEVICES, INC.